What Happened With Invo BioScience Stock Today?
What Happened With Invo BioScience Stock Today?
"We are confident that our expanded portfolio business model and combined assets have the potential to create significant value for both legacy and new shareholders," said Steve Shum, CEO of the combined company.INVO BioScience, Inc. (NASDAQ:INVO) shares soared Monday after the company announced it closed its merger with NAYA Biosciences.
納斯達克invo bioscience公司（NASDAQ:INVO）股價週一飆升，該公司宣佈已經完成與NAYA Biosciences的合併。
The Details: Invo BioScience said the combined company will continue to operate its fertility business as well as expand its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The company expects to change its name to Naya Biosciences and trade on the Nasdaq under the "NAYA" ticker.
詳情：Invo Bioscience表示，合併後的公司將繼續經營其生育業務，並將擴大業務重心至在腫瘤學和自身免疫疾病領域的臨床階段資產開發。該公司預計將更名爲Naya Biosciences，並在納斯達克上以"NAYA"逐筆明細交易。
The combined company will be led by Invo CEO Steve Shum, Invo CFO Andrea Goren and Dr. Daniel Teper, founder and former CEO of Naya Biosciences, who will be appointed as president of the combined company and CEO of the Naya Therapeutics subsidiary.
新公司將由Invo首席執行官Steve Shum、Invo首席財務官Andrea Goren以及Naya Biosciences的創始人和前首席執行官Daniel Teper領導，後者將被任命爲新公司的總裁兼Naya Therapeutics子公司的首席執行官。
"We are confident that our expanded portfolio business model and combined assets have the potential to create significant value for both legacy and new shareholders," said Steve Shum, CEO of the combined company.
"我們相信，我們擴大的投資組合業務模式和合並的資產有潛力爲老股東和新股東創造重要價值，"新公司首席執行官Steve Shum表示。
"Combining scalable, profitable revenues from our fertility business with the upside of innovative therapeutics optimizes risk-return for investors. In addition, the hub-and-spoke model allows for shared resources and talent to accelerate the development of our lean, agile subsidiaries," Shum said.
"將我們的生育業務的可擴展、盈利收入與創新治療方面的潛力相結合，優化了投資者的風險回報。此外，輪轂和輻條模式允許共享資源和人才，加速我們精益、敏捷子公司的發展，"Shum說道。
Invo shares climbed on heavy trading volume following Monday's announcement with more than 54 million shares traded in the session, according to data from Benzinga Pro.
根據Benzinga Pro的數據顯示，Invo股票在週一的宣佈後成交量大增，當天交易超過5400萬股。
INVO Price Action: According to Benzinga Pro, Invo BioScience shares are up 1.61% after-hours at $1.24 after gaining 92.55% in Monday's regular session.
INVO股價走勢：根據Benzinga Pro的數據顯示，Invo Bioscience股票在週一的常規交易中漲幅達到92.55%，盤後漲幅爲1.61%，報價爲1.24美元。
Read Also:
閱讀更多：
- What's Going On With First Solar Stock?
- 第一太陽能股票出現了什麼情況？
Photo: Shutterstock
圖片：shutterstock
譯文內容由第三人軟體翻譯。
